Using Cilostazol to prevent recurrent strokes in Africa
CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-Africa)
This study is looking at how well the medication cilostazol works to help prevent more strokes and heart problems in people who have already had a stroke, especially in sub-Saharan Africa, and it will also help improve local research on stroke care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern California Institute/res/edu NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10987338 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of cilostazol, a medication that may help prevent recurrent strokes and cardiac events in stroke survivors in sub-Saharan Africa. The study aims to assess how well cilostazol works when taken alongside aspirin or clopidogrel, particularly in a region where stroke outcomes are significantly poor. By focusing on a hybrid study design, the research will also build local capacity for stroke research and contribute valuable data to global stroke prevention efforts. Patients will be monitored for safety and efficacy over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are stroke survivors living in sub-Saharan Africa who are at high risk for recurrent strokes.
Not a fit: Patients who have not experienced a stroke or those with contraindications to cilostazol may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of recurrent strokes and improve overall cardiovascular health for patients in sub-Saharan Africa.
How similar studies have performed: Previous studies have shown cilostazol to be effective in reducing major cardiovascular events in other populations, suggesting potential for success in this new context.
Where this research is happening
San Francisco, United States
- Northern California Institute/res/edu — San Francisco, United States (Active)
Researchers
- Principal investigator: Ovbiagele, Bruce — Northern California Institute/res/edu
- Study coordinator: Ovbiagele, Bruce
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.